The most extensively studied targets in hematological diseases remain CD19 (54.41%), B-cell maturation antigen (BCMA) (16.12%), CD22 (9.60%), CD20 (7.01%), and CD7 (4.89%). This evidence concerns the gene TNFRSF17 and hematologic disorder.